Dexcom Inc Stock Current Valuation

DXCM Stock

USD 134.30 0.44 0.33%

Valuation analysis of DexCom Inc helps investors to measure DexCom's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 18th of April 2024, Enterprise Value Over EBITDA is likely to grow to 57.19. Also, Enterprise Value Multiple is likely to grow to 57.19. Fundamental drivers impacting DexCom's valuation include:

Price Book

25.3774

Enterprise Value

51.7 B

Enterprise Value Ebitda

57.124

Price Sales

14.4891

Forward PE

77.5194

Fairly Valued

Today

134.30

Please note that DexCom's price fluctuation is very steady at this time. Calculation of the real value of DexCom Inc is based on 3 months time horizon. Increasing DexCom's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.

Buy or Sell Advice Valuation Matrix

Our valuation method for DexCom Inc is useful when determining the fair value of the DexCom stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of DexCom. Since DexCom is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DexCom Stock. However, DexCom's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.

Historical

Market 134.3

Real 130.74

Target 137.0

Hype 135.27

The real value of DexCom Stock, also known as its intrinsic value, is the underlying worth of DexCom Inc Company, which is reflected in its stock price. It is based on DexCom's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of DexCom's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence DexCom's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.

128.47

Downside

130.74

Real Value

Target Odds

Above Odds

Below Odds

148.83

Upside

Estimating the potential upside or downside of DexCom Inc helps investors to forecast how DexCom stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DexCom more accurately as focusing exclusively on DexCom's fundamentals will not take into account other important factors:

Earnings

Estimates (0)

Low	Projected	High
0.21	0.27	0.34

Details

Hype

Prediction

Low	Estimated	High
133.00	135.27	137.54

Details

24 Analysts

Consensus

Low	Target Price	High
124.67	137.00	152.07

Details

DexCom Inc Company Current Valuation Analysis

DexCom's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current DexCom Current Valuation

51.74 B

Most of DexCom's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DexCom Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

DexCom Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for DexCom is extremely important. It helps to project a fair market value of DexCom Stock properly, considering its historical fundamentals such as Current Valuation. Since DexCom's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DexCom's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DexCom's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Total Current Assets	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Property Plant Equipment	Short Term Investments	Long Term Debt	Net Receivables	Short Term Debt	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Good Will	Capital Surpluse	Treasury Stock	Intangible Assets	Long Term Debt Total	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.95	1.0	0.81	0.75	0.99	0.81	0.98	0.98	0.97	0.97	0.4	0.76	1.0	0.81	0.84	0.88	-0.92	0.87	0.85	0.91	0.86	0.96	0.92	0.8
Total Stockholder Equity	0.98		0.89	0.98	0.73	0.8	0.96	0.72	0.94	0.97	0.93	0.92	0.42	0.65	0.99	0.8	0.87	0.92	-0.93	0.81	0.89	0.89	0.81	0.98	0.94	0.7
Net Debt	0.95	0.89		0.93	0.9	0.63	0.97	0.89	0.96	0.96	0.91	0.97	0.37	0.86	0.94	0.68	0.67	0.74	-0.83	0.89	0.7	0.79	0.81	0.88	0.81	0.89
Total Current Assets	1.0	0.98	0.93		0.76	0.73	0.99	0.77	0.95	0.98	0.98	0.96	0.36	0.73	0.99	0.83	0.86	0.9	-0.92	0.83	0.89	0.93	0.87	0.96	0.94	0.75
Retained Earnings	0.81	0.73	0.9	0.76		0.51	0.84	0.88	0.88	0.79	0.75	0.88	0.35	0.94	0.8	0.42	0.42	0.52	-0.69	0.87	0.44	0.54	0.65	0.74	0.62	0.92
Accounts Payable	0.75	0.8	0.63	0.73	0.51		0.7	0.58	0.75	0.71	0.58	0.67	0.81	0.41	0.75	0.61	0.8	0.77	-0.83	0.78	0.7	0.68	0.54	0.8	0.63	0.55
Total Liab	0.99	0.96	0.97	0.99	0.84	0.7		0.85	0.98	0.97	0.97	0.99	0.37	0.82	0.98	0.8	0.8	0.85	-0.91	0.89	0.82	0.9	0.88	0.94	0.89	0.84
Common Stock	0.81	0.72	0.89	0.77	0.88	0.58	0.85		0.89	0.76	0.75	0.91	0.47	0.91	0.78	0.57	0.54	0.56	-0.71	0.95	0.43	0.63	0.71	0.71	0.55	0.99
Property Plant Equipment	0.98	0.94	0.96	0.95	0.88	0.75	0.98	0.89		0.94	0.92	0.99	0.44	0.84	0.97	0.74	0.77	0.81	-0.9	0.93	0.74	0.82	0.82	0.92	0.83	0.88
Short Term Investments	0.98	0.97	0.96	0.98	0.79	0.71	0.97	0.76	0.94		0.95	0.94	0.37	0.71	0.98	0.76	0.8	0.87	-0.89	0.81	0.86	0.88	0.83	0.96	0.93	0.74
Long Term Debt	0.97	0.93	0.91	0.98	0.75	0.58	0.97	0.75	0.92	0.95		0.95	0.17	0.75	0.96	0.83	0.8	0.85	-0.87	0.76	0.86	0.93	0.9	0.91	0.93	0.73
Net Receivables	0.97	0.92	0.97	0.96	0.88	0.67	0.99	0.91	0.99	0.94	0.95		0.36	0.87	0.96	0.77	0.75	0.79	-0.87	0.91	0.73	0.85	0.86	0.9	0.83	0.9
Short Term Debt	0.4	0.42	0.37	0.36	0.35	0.81	0.37	0.47	0.44	0.37	0.17	0.36		0.27	0.38	0.23	0.41	0.38	-0.48	0.66	0.29	0.3	0.19	0.46	0.19	0.47
Current Deferred Revenue	0.76	0.65	0.86	0.73	0.94	0.41	0.82	0.91	0.84	0.71	0.75	0.87	0.27		0.74	0.52	0.42	0.47	-0.63	0.86	0.38	0.59	0.71	0.64	0.53	0.95
Net Tangible Assets	1.0	0.99	0.94	0.99	0.8	0.75	0.98	0.78	0.97	0.98	0.96	0.96	0.38	0.74		0.79	0.83	0.89	-0.92	0.84	0.86	0.88	0.84	0.97	0.93	0.77
Total Permanent Equity	0.81	0.8	0.68	0.83	0.42	0.61	0.8	0.57	0.74	0.76	0.83	0.77	0.23	0.52	0.79		0.9	0.84	-0.75	0.62	0.82	0.91	0.83	0.75	0.76	0.52
Good Will	0.84	0.87	0.67	0.86	0.42	0.8	0.8	0.54	0.77	0.8	0.8	0.75	0.41	0.42	0.83	0.9		0.97	-0.85	0.65	0.92	0.9	0.84	0.88	0.85	0.48
Capital Surpluse	0.88	0.92	0.74	0.9	0.52	0.77	0.85	0.56	0.81	0.87	0.85	0.79	0.38	0.47	0.89	0.84	0.97		-0.88	0.67	0.96	0.9	0.88	0.94	0.93	0.51
Treasury Stock	-0.92	-0.93	-0.83	-0.92	-0.69	-0.83	-0.91	-0.71	-0.9	-0.89	-0.87	-0.87	-0.48	-0.63	-0.92	-0.75	-0.85	-0.88		-0.81	-0.85	-0.87	-0.79	-0.93	-0.87	-0.68
Intangible Assets	0.87	0.81	0.89	0.83	0.87	0.78	0.89	0.95	0.93	0.81	0.76	0.91	0.66	0.86	0.84	0.62	0.65	0.67	-0.81		0.56	0.7	0.72	0.81	0.62	0.95
Long Term Debt Total	0.85	0.89	0.7	0.89	0.44	0.7	0.82	0.43	0.74	0.86	0.86	0.73	0.29	0.38	0.86	0.82	0.92	0.96	-0.85	0.56		0.92	0.82	0.91	0.95	0.4
Short Long Term Debt	0.91	0.89	0.79	0.93	0.54	0.68	0.9	0.63	0.82	0.88	0.93	0.85	0.3	0.59	0.88	0.91	0.9	0.9	-0.87	0.7	0.92		0.89	0.87	0.89	0.59
Long Term Investments	0.86	0.81	0.81	0.87	0.65	0.54	0.88	0.71	0.82	0.83	0.9	0.86	0.19	0.71	0.84	0.83	0.84	0.88	-0.79	0.72	0.82	0.89		0.85	0.84	0.69
Net Invested Capital	0.96	0.98	0.88	0.96	0.74	0.8	0.94	0.71	0.92	0.96	0.91	0.9	0.46	0.64	0.97	0.75	0.88	0.94	-0.93	0.81	0.91	0.87	0.85		0.95	0.69
Net Working Capital	0.92	0.94	0.81	0.94	0.62	0.63	0.89	0.55	0.83	0.93	0.93	0.83	0.19	0.53	0.93	0.76	0.85	0.93	-0.87	0.62	0.95	0.89	0.84	0.95		0.52
Capital Stock	0.8	0.7	0.89	0.75	0.92	0.55	0.84	0.99	0.88	0.74	0.73	0.9	0.47	0.95	0.77	0.52	0.48	0.51	-0.68	0.95	0.4	0.59	0.69	0.69	0.52

Click cells to compare fundamentals

DexCom Current Valuation Historical Pattern

Today, most investors in DexCom Stock are looking for potential investment opportunities by analyzing not only static indicators but also various DexCom's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of DexCom current valuation as a starting point in their analysis.

DexCom Current Valuation

Timeline

Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Competition

Predict DexCom

Enterprise Value Over Time

In accordance with the recently published financial statements, DexCom Inc has a Current Valuation of 51.74 B. This is 260.26% higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is significantly lower than that of the firm.

DexCom Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.

DexCom is currently under evaluation in current valuation category among related companies.

DexCom ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DexCom's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DexCom's managers, analysts, and investors.

Environment Score

Governance Score

Social Score

DexCom Fundamentals

	Return On Equity	0.26
	Return On Asset	0.0641
	Profit Margin	0.15 %
	Operating Margin	0.21 %
	Current Valuation	51.74 B
	Shares Outstanding	385.52 M
	Shares Owned By Insiders	0.41 %
	Shares Owned By Institutions	99.59 %
	Number Of Shares Shorted	14.57 M
	Price To Earning	245.31 X
	Price To Book	25.38 X
	Price To Sales	14.49 X
	Revenue	3.62 B
	Gross Profit	1.88 B
	EBITDA	916.7 M
	Net Income	541.5 M
	Cash And Equivalents	2.37 B
	Cash Per Share	6.14 X
	Total Debt	2.59 B
	Debt To Equity	1.17 %
	Current Ratio	3.77 X
	Book Value Per Share	5.37 X
	Cash Flow From Operations	748.5 M
	Short Ratio	4.32 X
	Earnings Per Share	1.31 X
	Price To Earnings To Growth	2.53 X
	Target Price	151.05
	Number Of Employees	9.5 K
	Beta	1.21
	Market Capitalization	52.63 B
	Total Asset	6.26 B
	Retained Earnings	1.02 B
	Working Capital	2.87 B
	Current Asset	231.3 M
	Current Liabilities	66.9 M
	Net Asset	6.26 B

About DexCom Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with DexCom

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.

Moving against DexCom Stock

0.66	TFX	Teleflex Incorporated Financial Report 2nd of May 2024	Pair Corr
0.63	IVP	Inspire Veterinary	Pair Corr
0.59	EMBC	Embecta Corp Financial Report 10th of May 2024	Pair Corr
0.52	AHG	Akso Health Group	Pair Corr
0.5	DYNT	Dynatronics Financial Report 9th of May 2024	Pair Corr

The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.

The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:

How To Invest In DexCom

Details

Is DexCom Stock a good investment?

Details

What is DexCom's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out DexCom Piotroski F Score and DexCom Altman Z Score analysis.

Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for DexCom Stock analysis

When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.

	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	AI Investment Finder Use AI to screen and filter profitable investment opportunities
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Global Correlations Find global opportunities by holding instruments from different markets
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency

Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.81

Earnings Share

1.31

Revenue Per Share

9.384

Quarterly Revenue Growth

0.269

Return On Assets

0.0641

The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dexcom Inc Stock Current Valuation

DexCom Inc Company Current Valuation Analysis

Enterprise Value

Market Cap + Debt

-

Cash

Current DexCom Current Valuation

DexCom Current Valuation Driver Correlations

DexCom Current Valuation Historical Pattern

DexCom Current Valuation Peer Comparison

DexCom ESG Sustainability

DexCom Fundamentals

About DexCom Fundamental Analysis

Pair Trading with DexCom

Moving against DexCom Stock

Complementary Tools for DexCom Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY